Applicant, as named in the Orange Book

Amgen Inc

Next listed expiry: Otezla on 29 Nov 2034. 3 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Otezla · 3 strengths apremilast	apremilast	205437	29 Nov 2034	patent
Lumakras · 3 strengths sotorasib	sotorasib	214665	15 Sep 2040	patent, carve-out possible
Otezla Xr apremilast	apremilast	210745	27 May 2042	patent

Recent events

24 Oct 2026Otezla · Exclusivity expires within 90 days PED20 Jan 2027
24 Oct 2026Otezla · Exclusivity expires within 90 days PED19 Jan 2027
24 Oct 2026Otezla · Exclusivity expires within 90 days PED20 Jan 2027
24 Oct 2026Otezla · Exclusivity expires within 90 days PED19 Jan 2027
24 Oct 2026Otezla · Exclusivity expires within 90 days PED20 Jan 2027
24 Oct 2026Otezla · Exclusivity expires within 90 days PED19 Jan 2027
24 Oct 2026Corlanor · Enters 12-month window basis: patent12 Jun 2027
24 Oct 2026Corlanor · Enters 12-month window basis: patent12 Jun 2027
24 Oct 2026Otezla Xr · Exclusivity expires within 90 days PED20 Jan 2027
24 Oct 2026Otezla Xr · Exclusivity expires within 90 days PED19 Jan 2027
24 Oct 2026Corlanor · Enters 12-month window basis: patent12 Dec 2026